OVKATE is a human ovarian cancer cell line established from the primary ovarian tumor of a 40-year-old female with serous papillary adenocarcinoma. At the time of establishment, OVKATE cells were tumorigenic in nude mice after both Intraperitoneal and subcutaneous (s.c.) transplantation. However, more recent studies have shown that OVKATE forms only after subcutaneous implantation[1]. The cells harbor an R282W mutation in the TP53 gene, resulting in a loss of TP53 function. OVKATE cells have been also reported to be resistant to platinum-based agents[2].
OVKATE is a significant cancer cell model of primary high-grade serous adenocarcinoma (HGSOC). The generation of xenograft models OVKATE enables a deeper understanding and preclinical drug development for ovarian cancer research.
[1] A. K. Mitra et al., “In vivo tumor growth of high-grade serous ovarian cancer cell lines,” Gynecol. Oncol., vol. 138, no. 2, pp. 372–377, Aug. 2015, doi: 10.1016/j.ygyno.2015.05.040.
[2] S. Yamaguchi, Y. Maida, M. Yasukawa, T. Kato, M. Yoshida, and K. Masutomi, “...... Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells,” PLoS ONE, vol. 9, no. 11, p. e112438, Nov. 2014, doi: 10.1371/journal.pone.0112438.
